Difference between revisions of "MEDICATION-MIDODRINE"
From NeuroRehab.wiki
(Imported from text file) |
(Imported from text file) |
||
Line 4: | Line 4: | ||
==Reference(s)== | ==Reference(s)== | ||
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. | Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. | ||
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons. | <br/>American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons. | ||
[[Category:Medication]] | [[Category:Medication]] | ||
[[Category:Advanced Life Support]] | [[Category:Advanced Life Support]] |
Revision as of 01:50, 17 December 2022
1. Great drug! Pro-drug: desglymidodrine.
2. Alpha-1 receptor agonist: works on arteries & veins.
3. Peak action in 1-2 hrs post-oral intake, lasting 3-4 hrs. 94% bioavailability.
4. Useful in the ward for patients with sepsis who have been adequately fluid resuscitated. Can also be used in postural hypotension.
5. Dosage: 10 mg Q6h - 20 mg Q6h; just don't send patients home on it! Wean over 3 days.
Reference(s)
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council.
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons.